Clinical trials help medical experts develop new drugs and treatments that can improve the way diseases are diagnosed, make better and safer surgical procedures, and develop medical devices that can improve the lives of many.
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved. After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant’s ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
-
ARrest RESpiraTory Failure From PNEUMONIA
on December 10, 2019 at 5:00 pm
Conditions: Pneumonia; Hypoxemia; Acute Respiratory FailureInterventions: Drug: Inhaled budesonide and formoterol; Drug: Inhaled placeboSponsors: Stanford University; National Heart, Lung, and Blood Institute (NHLBI); […]
-
Wearable Technology to Assess Gait Function in SMA and DMD
on December 10, 2019 at 5:00 pm
Conditions: Spinal Muscular Atrophy Type 3; Duchenne Muscular DystrophyIntervention: Sponsors: Columbia University; Muscular Dystrophy Association; Stevens Institute of TechnologyRecruiting
-
Financial Incentives to Improve Medication Adherence
on December 10, 2019 at 5:00 pm
Conditions: Schizophrenia; Schizo Affective Disorder; Bipolar Disorder; DepressionIntervention: Other: Wellth - Financial IncentivesSponsor: Northwell HealthRecruiting
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
on December 10, 2019 at 5:00 pm
Conditions: Brain Metastases; Leptomeningeal MetastasisInterventions: Drug: GDC-0084; Radiation: whole brain radiation therapy radiationSponsors: Memorial Sloan Kettering Cancer Center; Kazia TherapeuticsRecruiting
-
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
on December 10, 2019 at 5:00 pm
Condition: Hypertension, PulmonaryInterventions: Other: Blood Sample; Device: ReCIVA® Breath Sampler and CASPER air supply unitSponsor: Janssen Research & Development, LLCNot yet recruiting
-
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
on December 10, 2019 at 5:00 pm
Condition: Myeloproliferative NeoplasmIntervention: Drug: DOACsSponsor: Fondazione per la Ricerca Ospedale MaggioreRecruiting
-
Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
on December 9, 2019 at 5:00 pm
Condition: Persistent Atrial FibrillationIntervention: Device: Insertable Cardiac MonitorSponsors: University of Rochester; Biotronik, Inc.Not yet recruiting
-
A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative,...
on December 9, 2019 at 5:00 pm
Condition: Breast CancerInterventions: Drug: GDC-0077; Drug: Placebo; Drug: Palbociclib; Drug: FulvestrantSponsor: Hoffmann-La RocheNot yet recruiting